ClinicalTrials.gg
RecruitingNCT07295483Updated Mar 12, 2026

Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)

An observational study in Persistent COVID Condition, sponsored by Instituto de Investigación Biomédica de Salamanca. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Instituto de Investigación Biomédica de Salamanca · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Planned enrollment
2nd of 13
400 · median 184
Started
2026
with 4 others
Observational
13 of 52
4 open now
Primary completion
2029-03
later than 15 of 15 live
Registered
44th of 52
by date

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2026, is one of 13 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 44th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.

The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.

Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.

Read the detailed description

The study includes a citizen participation component through the IBSAL Citizen Committee for review and dissemination of results. A prospective observational cohort study following 400 adults with a confirmed diagnosis of long COVID, previously enrolled in the BioICOPER baseline study.

Participants will undergo reevaluation four years after their initial inclusion, assessing:

  • Clinical symptoms (fatigue, dyspnea, sleep, cognition, nutrition, frailty).
  • Lifestyle factors (physical activity, diet, alcohol and tobacco use).
  • Vascular structure and function using carotid ultrasound, pulse wave velocity (SphygmoCor®, Vasera®), and retinal imaging.
  • Proteomic profiling and quantification of SARS-CoV-2 N and S proteins using ELISA and mass spectrometry.
  • Predictive modeling using artificial intelligence (AI) and bioinformatics methods (ESALAB group).

The study will identify biological, vascular, and behavioral determinants of long COVID progression, aiming to build predictive models to support personalized medicine.

03

Conditions studied

  • Persistent COVID Condition

Keywords

  • Post-acute COVID syndrome
  • Vascular aging
  • Proteomics
  • Biomarkers
  • Machine learning
  • Persistent COVID
  • Artificial Intelligence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults previously enrolled in the BioICOPER study with a clinical diagnosis of long COVID.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years old.
  • Confirmed previous SARS-CoV-2 infection.
  • Diagnosis of long COVID according to WHO criteria.
  • Participation in the baseline BioICOPER study.
  • Signed for re-evaluation.

Exclusion criteria

Exclusion Criteria:

  • Acute illness preventing participation.
  • Cognitive or physical impairment limiting data collection.
  • Withdrawal of .
  • Age \< 18 years old
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • BioICOPER Long COVID Cohort

    Adults previously enrolled in the BioICOPER study with a clinical diagnosis of long COVID.

    Other: BioICOPER Long COVID Cohort

Interventions

  • OtherBioICOPER Long COVID Cohort

    This observational cohort includes 400 adult participants previously enrolled in the baseline BioICOPER study (2021-2023), who had a confirmed diagnosis of long COVID (persistent COVID-19) according to WHO criteria. Participants will undergo a comprehensive four-year follow-up assessment to evaluate clinical evolution, vascular function, and biological markers of disease persistence and recovery. There is no intervention assigned by the investigators - participants will continue their usual medical care. The study will observe natural disease progression and its association with biomarkers, vascular measurements, and lifestyle factors.

06

What researchers measure

Primary outcomes

  1. Progression of vascular stiffness measured by carotid-femoral pulse wave velocity (cfPWV)

    Carotid-femoral pulse wave velocity will be assessed as the gold-standard measure of arterial stiffness, using the SphygmoCor® system. The study will evaluate the longitudinal change in cfPWV between baseline (BioICOPER inclusion) and the 4-year follow-up visit, in order to determine whether long COVID is associated with accelerated vascular aging.

    Time frame: From baseline to 48-month follow-up

Secondary outcomes

  1. Change in Fatigue Severity Score (FSS)

    Fatigue assessed using a validated fatigue scale (Fatigue Severity Scale, FSS). The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on you. The FSS is a short questionnaire that requires the patient to rate their level of fatigue. The FSS questionnaire contains nine statements that rate the severity of their fatigue symptoms. the patient needs to read each statement and circle a number from 1 to 7, based on how accurately it reflects their condition during the previous week and the extent to which they agree or disagree that the statement applies to them. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. The goal of this outcome is to determine how fatigue severity evolves and its association with biomarkers and vascular parameters.

    Time frame: From baseline to 4-year follow-up.

  2. Change in Health-Related Quality of Life (EQ-5D-5L or SF-36)

    EQ-5D-5L is a health-related quality of life survey that uses five questions, each with five severity levels, to measure health status across the dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Health state profile: A person's answers create a five-number profile that describes their current health state. Scoring: This profile can be used to calculate a single index score that represents health-related quality of life. This score ranges from 0 (death) to 1 (full health). It assesses eight health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The SF-36 survey grades health by scoring responses on eight different health domains, which are then converted to a 0-100 scale where higher scores indicate better health. A score of 100 represents the best possible health in that category, while 0 represents the worst.

    Time frame: From baseline to 4 years.

  3. Change in Cognitive Function (Montreal Cognitive Assessment, MoCA)

    Evaluate cognitive impairment associated with long COVID using the Montreal Cognitive Assessment, which is a 10-minute screening test used to detect mild cognitive impairment in adults. It is a 30-point test that evaluates several cognitive domains, including memory, attention, language, visuospatial skills, executive functions, and orientation. A score of 26 or above is considered a normal result, while lower scores may indicate some level of cognitive dysfunction. The goal of this assesment is to identify determinants of neurocognitive persistence or recovery.

    Time frame: Baseline to 4 years

  4. Change in Physical Activity (WHO Physical Activity Questionnaire + 7-day pedometer readings)

    Objectively and subjectively measure physical activity levels using both WHO Physical Activity Questionnaire and 7-day pedometer readings. The WHO Physical Activity Questionnaire is a 16 question instrument that assesses physical activity participation in three domains (activity at work, travel to and from places, and recreational activities) as well as sedentary behavior. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc. The use of the pedometer only completes the questionnaire, hence both variables need to be meassured simultaneously and interpret them together in order to determine changes in physical activity.

    Time frame: Baseline to 4 years.

  5. Change in Adherence to the Mediterranean Diet (PREDIMED Questionnaire)

    Evaluate diet quality and its relation to metabolic and vascular outcomes. The PREDIMED questionnaire is a screening tool used in the PREDIMED study to assess adherence to the Mediterranean diet. The most common version is a 14-point questionnaire that asks about frequency of consumption of certain foods like olive oil, nuts, fruits, vegetables, and fish, and the limited intake of red meat, butter, and sugary drinks. Participants receive a score of 0 or 1 for each question, and the total score is used to classify their diet as low, moderate, or high in Mediterranean adherence. The goal of this outome is to assess dietary influence on systemic inflammation, endothelial function, and metabolic health.

    Time frame: Baseline to 4 years.

  6. Change in Body Composition (InBody 230 Bioimpedance Analysis)

    The InBody 230 Bioimpedance Analysis is a non-invasive test that measures body composition by sending a mild electrical current through the body. It uses a technique called segmental multifrequency bioelectrical impedance to provide detailed information on body fat, skeletal muscle mass, and body water in the torso, arms, and legs. This analysis offers a more comprehensive picture of your health than a standard scale, providing data like Basal Metabolic Rate (BMR) and Body Mass Index (BMI). The goal od this outcome is to explore links between body composition and cardiovascular risk in long COVID.

    Time frame: Baseline to 4 years.

  7. Change in Biomarkers of Endothelial and Inflammatory Activity

    This Outcome Measure reflects a single assessment in which multiple plasma biomarkers (e.g., ICAM-1, VCAM-1, Endothelin-1, TNF-α, IL-10, and additional cytokines) are quantified within the same measurement framework. All biomarkers are measured using ELISA and proteomic techniques and reported in consistent concentration units (e.g., pg/mL or ng/mL) as appropriate for each assay. Although multiple biomarkers are included, they represent components of one integrated biomarker panel evaluating endothelial and inflammatory activity. No aggregation of different units is performed; instead, each biomarker's concentration is reported separately under this single Outcome Measure to characterize molecular pathways involved in long-term vascular and inflammatory changes in long COVID.

    Time frame: Baseline to 4 years

  8. Change in Proteomic Profiles

    Analysis of proteomic profiling of serum/plasma using advanced mass spectrometry to identify proteins related to fatigue, inflammation, and vascular aging to discover predictive biomarkers for persistent symptoms and disease progression.

    Time frame: 4 years

  9. SARS-CoV-2 Protein Quantification (N and S Proteins)

    In order to explore persistence of viral antigens and relationship with ongoing symptoms and vascular damage, plasma will be qualified using ELISA.

    Time frame: 4 years

  10. AI-Based Predictive Model Performance

    To develop and validate AI-based tools for risk stratification and personalized management using supervised learning (Random Forest, XGBoost, Neural Networks) trained on 70% of the cohort, validated on 30%. The machine learning models will combine clinical, vascular, and proteomic variables to predict disease trajectory.

    Time frame: Baseline to 4 years.

07

Study locations

1 of 1 sites recruiting
  • Av. de Portugal 83. Planta 2
    Salamanca, Salamanca 37005, Spain
    Recruiting
    • Manuel Angel Gómez Marcos, Md, PhD · Contactmagomez@usal.es · +346751143551
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

Access criteria: Sharing Access Criteria: Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 37 months is above that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 19, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Jun 2029
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07295483
Lead sponsor
Instituto de Investigación Biomédica de Salamanca
Collaborators
Carlos III Health Institute
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Feb 9, 2026
Primary completion
Mar 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Manuel Angel Gómez Marcos, MD, PhD
Contact
magomez@usal.es
+346751143551
Manuel Angel Gomez Marcos, MD, PhD
principal investigator · Centro Asistencial Universitario de Salamanca (CAUSA)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion